Get started
ABBVIEABBVIEABBVIE

ABBVIE

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

4ABBV chart


Full chart

Key facts today

AbbVie reported a 37.2% decline in Q3 2023 Humira sales at $2.2 billion. Skyrizi and Rinvoq contributed to a 3.9% rise in immunology revenue, while total revenue increased to $14.5 billion, up 3.8%.
Citi keeps its buy rating on AbbVie Inc. (ABBV) after the emraclidine schizophrenia study failed. The firm removed emraclidine from its model and lowered the stock's target price from $226 to $215.
Citigroup lowered AbbVie Inc. (ABBV) price target to $215 from $226. Analysts rate the stock as outperform, with targets between $170 and $240.
Analyze the impactAnalyze the impact

4ABBV upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪328.92 B‬ EUR
Dividend yield (indicated)
3.29%
Price to earnings Ratio (TTM)
69.28
Basic EPS (TTM)
2.58 EUR
Net income (FY)
‪4.37 B‬ EUR
Revenue (FY)
‪49.21 B‬ EUR
Shares float
‪1.77 B‬
Beta (1Y)
−0.19

Employees


Employees (FY)
‪50 K‬
Change (1Y)
0
Revenue / Employee (1Y)
‪1.09 M‬ EUR
Net income / Employee (1Y)
‪96.40 K‬ EUR

About AbbVie Inc.


Sector
Health Technology
CEO
Robert A. Michael
Headquarters
North Chicago
Website
abbvie.com
Founded
2011
FIGI
BBG00LXXK9T1
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

4ABBV news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

4ABBV highest yielding bonds


A
ACT4176286
Allergan Funding SCS 4.85% 15-JUN-2044
Yield to maturity
6.90%
Maturity date
Jun 15, 2044
A
ACT3910526
Actavis, Inc. 4.625% 01-OCT-2042
Yield to maturity
6.88%
Maturity date
Oct 1, 2042
A
ACT4218883
Allergan Funding SCS 4.75% 15-MAR-2045
Yield to maturity
6.44%
Maturity date
Mar 15, 2045
A
ACT4218882
Allergan Funding SCS 4.55% 15-MAR-2035
Yield to maturity
5.75%
Maturity date
Mar 15, 2035
ABBV4911706
AbbVie Inc. 3.2% 21-NOV-2029
Yield to maturity
5.70%
Maturity date
Nov 21, 2029
ABBV5759196
AbbVie Inc. 5.5% 15-MAR-2064
Yield to maturity
5.39%
Maturity date
Mar 15, 2064
ABBV5068388
AbbVie Inc. 4.625% 01-OCT-2042
Yield to maturity
5.37%
Maturity date
Oct 1, 2042
ABBV5759195
AbbVie Inc. 5.4% 15-MAR-2054
Yield to maturity
5.28%
Maturity date
Mar 15, 2054
ABBV4693583
AbbVie Inc. 4.875% 14-NOV-2048
Yield to maturity
5.27%
Maturity date
Nov 14, 2048
4ABB
ABBVIE 15/45
Yield to maturity
5.27%
Maturity date
May 14, 2045
ABBV5068389
AbbVie Inc. 4.85% 15-JUN-2044
Yield to maturity
5.24%
Maturity date
Jun 15, 2044

Explore more bonds 

Sparks


Curated watchlists where 4ABBV is featured.

See all sparks 

Frequently Asked Questions


The current price of 4ABBV is 166.18 EUR — it has increased by 1.10% in the past 24 hours. Watch ABBVIE stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EUROTLX exchange ABBVIE stocks are traded under the ticker 4ABBV.
4ABBV stock has fallen by −0.16% compared to the previous week, the month change is a 6.20% rise, over the last year ABBVIE has showed a 29.63% increase.
We've gathered analysts' opinions on ABBVIE future price: according to them, 4ABBV price has a max estimate of 225.28 EUR and a min estimate of 159.57 EUR. Watch 4ABBV chart and read a more detailed ABBVIE stock forecast: see what analysts think of ABBVIE and suggest that you do with its stocks.
4ABBV reached its all-time high on Nov 6, 2024 with the price of 189.06 EUR, and its all-time low was 57.50 EUR and was reached on Jun 25, 2019. View more price dynamics on 4ABBV chart.
See other stocks reaching their highest and lowest prices.
4ABBV stock is 15.67% volatile and has beta coefficient of −0.19. Track ABBVIE stock price on the chart and check out the list of the most volatile stocks — is ABBVIE there?
Today ABBVIE has the market capitalization of ‪330.92 B‬, it has increased by 7.63% over the last week.
Yes, you can track ABBVIE financials in yearly and quarterly reports right on TradingView.
ABBVIE is going to release the next earnings report on Jan 29, 2025. Keep track of upcoming events with our Earnings Calendar.
4ABBV earnings for the last quarter are 2.69 EUR per share, whereas the estimation was 2.62 EUR resulting in a 2.74% surprise. The estimated earnings for the next quarter are 2.79 EUR per share. See more details about ABBVIE earnings.
ABBVIE revenue for the last quarter amounts to ‪12.99 B‬ EUR, despite the estimated figure of ‪12.83 B‬ EUR. In the next quarter, revenue is expected to reach ‪13.89 B‬ EUR.
4ABBV net income for the last quarter is ‪1.39 B‬ EUR, while the quarter before that showed ‪1.27 B‬ EUR of net income which accounts for 9.71% change. Track more ABBVIE financial stats to get the full picture.
Yes, 4ABBV dividends are paid quarterly. The last dividend per share was 1.42 EUR. As of today, Dividend Yield (TTM)% is 3.11%. Tracking ABBVIE dividends might help you take more informed decisions.
ABBVIE dividend yield was 3.87% in 2023, and payout ratio reached 220.33%. The year before the numbers were 3.53% and 86.17% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 12, 2024, the company has ‪50.00 K‬ employees. See our rating of the largest employees — is ABBVIE on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ABBVIE EBITDA is ‪22.75 B‬ EUR, and current EBITDA margin is 49.30%. See more stats in ABBVIE financial statements.
Like other stocks, 4ABBV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABBVIE stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ABBVIE technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ABBVIE stock shows the buy signal. See more of ABBVIE technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.